197 related articles for article (PubMed ID: 30053488)
1. Dosing considerations for inhaled biologics.
Ferrati S; Wu T; Kanapuram SR; Smyth HDC
Int J Pharm; 2018 Oct; 549(1-2):58-66. PubMed ID: 30053488
[TBL] [Abstract][Full Text] [Related]
2. Dry powder pharmaceutical biologics for inhalation therapy.
Chang RYK; Chow MYT; Khanal D; Chen D; Chan HK
Adv Drug Deliv Rev; 2021 May; 172():64-79. PubMed ID: 33705876
[TBL] [Abstract][Full Text] [Related]
3. Advances in device and formulation technologies for pulmonary drug delivery.
Chan JG; Wong J; Zhou QT; Leung SS; Chan HK
AAPS PharmSciTech; 2014 Aug; 15(4):882-97. PubMed ID: 24728868
[TBL] [Abstract][Full Text] [Related]
4. Dry powder inhalers: An overview of the in vitro dissolution methodologies and their correlation with the biopharmaceutical aspects of the drug products.
Velaga SP; Djuris J; Cvijic S; Rozou S; Russo P; Colombo G; Rossi A
Eur J Pharm Sci; 2018 Feb; 113():18-28. PubMed ID: 28887232
[TBL] [Abstract][Full Text] [Related]
5. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
Lau M; Young PM; Traini D
Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
[TBL] [Abstract][Full Text] [Related]
6. Dry powder inhalation: past, present and future.
de Boer AH; Hagedoorn P; Hoppentocht M; Buttini F; Grasmeijer F; Frijlink HW
Expert Opin Drug Deliv; 2017 Apr; 14(4):499-512. PubMed ID: 27534768
[TBL] [Abstract][Full Text] [Related]
7. Formulation techniques for high dose dry powders.
Brunaugh AD; Smyth HDC
Int J Pharm; 2018 Aug; 547(1-2):489-498. PubMed ID: 29778822
[TBL] [Abstract][Full Text] [Related]
8. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
[TBL] [Abstract][Full Text] [Related]
9. Low powder mass filling of dry powder inhalation formulations.
Eskandar F; Lejeune M; Edge S
Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
[TBL] [Abstract][Full Text] [Related]
10. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
11. In vitro dry powder inhaler formulation performance considerations.
Ziffels S; Bemelmans NL; Durham PG; Hickey AJ
J Control Release; 2015 Feb; 199():45-52. PubMed ID: 25497311
[TBL] [Abstract][Full Text] [Related]
12. The application of Quality by Design framework in the pharmaceutical development of dry powder inhalers.
Buttini F; Rozou S; Rossi A; Zoumpliou V; Rekkas DM
Eur J Pharm Sci; 2018 Feb; 113():64-76. PubMed ID: 29104067
[TBL] [Abstract][Full Text] [Related]
13. Modeling the performance of carrier-based dry powder inhalation formulations: Where are we, and how to get there?
Elsayed MMA; Shalash AO
J Control Release; 2018 Jun; 279():251-261. PubMed ID: 29574042
[TBL] [Abstract][Full Text] [Related]
14. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
Muralidharan P; Hayes D; Mansour HM
Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
[TBL] [Abstract][Full Text] [Related]
15. Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis.
Young PM; Salama RO; Zhu B; Phillips G; Crapper J; Chan HK; Traini D
Drug Dev Ind Pharm; 2015 May; 41(5):859-65. PubMed ID: 24811055
[TBL] [Abstract][Full Text] [Related]
16. The nanoscale in pulmonary delivery. Part 2: formulation platforms.
Rogueda PG; Traini D
Expert Opin Drug Deliv; 2007 Nov; 4(6):607-20. PubMed ID: 17970664
[TBL] [Abstract][Full Text] [Related]
17. The dispersion behaviour of dry powder inhalation formulations cannot be assessed at a single inhalation flow rate.
Grasmeijer F; de Boer AH
Int J Pharm; 2014 Apr; 465(1-2):165-8. PubMed ID: 24548720
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.
Weers J; Clark A
Pharm Res; 2017 Mar; 34(3):507-528. PubMed ID: 27738953
[TBL] [Abstract][Full Text] [Related]
19. Influence of Formulation Factors on the Aerosol Performance and Stability of Lysozyme Powders: a Systematic Approach.
Ferrati S; Wu T; Fuentes O; Brunaugh AD; Kanapuram SR; Smyth HDC
AAPS PharmSciTech; 2018 Oct; 19(7):2755-2766. PubMed ID: 29488193
[TBL] [Abstract][Full Text] [Related]
20. Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling.
Vulović A; Šušteršič T; Cvijić S; Ibrić S; Filipović N
Eur J Pharm Sci; 2018 Feb; 113():171-184. PubMed ID: 29054499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
